COPD Fundamentals
COPD is characterised by persistent, progressive airflow limitation associated with an enhanced chronic inflammatory response to noxious particles or gases. Diagnosis requires post-bronchodilator FEV1/FVC <0.70 (GOLD criteria).
GOLD Spirometric Classification (FEV1% predicted)
| Grade | FEV1 % Predicted | Severity | Key Feature |
|---|---|---|---|
| GOLD 1 | ≥ 80% | Mild | Often asymptomatic; FEV1/FVC <0.70 |
| GOLD 2 | 50–79% | Moderate | Increasing breathlessness on exertion |
| GOLD 3 | 30–49% | Severe | Further dyspnoea, reduced exercise capacity |
| GOLD 4 | < 30% | Very Severe | Chronic respiratory failure, poor quality of life |
Post-bronchodilator spirometry required for all classifications. FEV1/FVC <0.70 confirms airflow limitation.
ABCD Assessment Tool
Two Domains
- Exacerbation History: 0-1 (low risk, not hospitalised) vs ≥2 or ≥1 leading to hospitalisation (high risk)
- Symptom Burden: mMRC ≥2 or CAT ≥10 = more symptoms
| Group | Exacerbations | Symptoms |
|---|---|---|
| A | Low risk | Less symptoms |
| B | Low risk | More symptoms |
| C | High risk | Less symptoms |
| D | High risk | More symptoms |
mMRC scale 0-4; CAT score 0-40 (≥10 = significant impact)
mMRC Dyspnoea Scale
- Grade 0: Breathless only with strenuous exercise
- Grade 1: Breathless hurrying on level ground or walking up a slight hill
- Grade 2: Walks slower than peers or stops for breath on level ground
- Grade 3: Stops for breath after 100m or after a few minutes on level ground
- Grade 4: Too breathless to leave house, or breathless when dressing
Bronchodilator Pharmacotherapy Sequence
| Class | Example Drugs | Indication | Duration |
|---|---|---|---|
| SABA (Short-Acting β2-Agonist) | Salbutamol, Terbutaline | PRN relief all groups | 4–6 hours |
| SAMA (Short-Acting Muscarinic Ant.) | Ipratropium | PRN or regular, Group A/B if inadequate | 6–8 hours |
| LABA (Long-Acting β2-Agonist) | Formoterol, Salmeterol, Indacaterol | Group B/C/D maintenance | 12–24 hours |
| LAMA (Long-Acting Muscarinic Ant.) | Tiotropium, Umeclidinium, Aclidinium | Group C/D preferred; also B if inadequate | 24 hours |
| LABA+LAMA (Dual) | Umeclidinium/Vilanterol, Tiotropium/Olodaterol | Group B if breathless; Group D first-line | 24 hours |
ICS Indications
Inhaled Corticosteroids should be added (as ICS+LABA or triple therapy) when:
- Blood eosinophils ≥300 cells/µL — strong predictor of ICS response
- Blood eosinophils 100–300 cells/µL with ≥2 exacerbations/year or ≥1 hospitalisation
- History of frequent exacerbations (≥2 moderate/year)
- Concomitant or suspected asthma-COPD overlap
Avoid ICS if: eosinophils <100 cells/µL, history of recurrent pneumonia, or mycobacterial infection
Triple Therapy (ICS+LABA+LAMA)
Indicated for Group D patients with:
- High exacerbation burden despite dual bronchodilation
- Eosinophils ≥100 cells/µL
- Significant symptom burden (CAT ≥10)
Evidence: IMPACT trial — triple therapy reduced moderate/severe exacerbations by 25% vs LAMA alone and 15% vs ICS+LABA
FF/UMEC/VI BDP/FOR/GLY
Long-Term Oxygen Therapy (LTOT) Criteria
| Criterion | Threshold | Additional Condition |
|---|---|---|
| Standard LTOT | PaO2 <7.3 kPa (55 mmHg) on air at rest | Stable state — measure twice ≥3 weeks apart |
| LTOT with complications | PaO2 7.3–8 kPa (55–60 mmHg) | PLUS polycythaemia (Hct >55%), cor pulmonale (RHF/oedema), or pulmonary hypertension |
| Duration requirement | Minimum ≥15 hours/day | Includes sleep; mortality benefit shown with ≥18h/day (NOTT trial) |
| Smoking status | Non-smoking mandatory | Fire risk; oxidative stress negates benefit |
LTOT does NOT improve survival in patients with moderate hypoxaemia (PaO2 7.3–8 kPa without complications) — LOTT trial 2016.
Surgical & Interventional Options
Lung Volume Reduction Surgery (LVRS)
- Upper-lobe predominant emphysema with low exercise capacity
- NETT trial: improved survival in specific subgroup
- Bronchoscopic options: endobronchial valves (Zephyr), coils
Bullectomy
- Giant bullae (>1/3 of hemithorax) compressing normal lung
- Significant dyspnoea refractory to medical therapy
- Improves FEV1, RV, and exercise capacity
Lung Transplantation
- GOLD 4 with BODE index ≥7 or rapid FEV1 decline
- Bilateral sequential preferred for COPD/emphysema
- BODE index: BMI, FEV1%, dyspnoea (mMRC), 6MWT
Pulmonary Rehabilitation Programme
Cochrane Review Evidence: Pulmonary rehabilitation improves 6MWT by +60m (MCID), reduces hospital admissions, improves health-related quality of life (HRQoL), and reduces dyspnoea. Effects last 12–24 months post-programme. (McCarthy et al., Cochrane 2015)
Programme Structure
- Duration: 6–8 weeks minimum (some programmes extend to 12 weeks)
- Frequency: 2–3 supervised sessions per week
- Format: Supervised outpatient (gold standard), home-based, or telerehabilitation
- Entry point: During admission or within 4 weeks post-exacerbation (early PR)
- Class size: Typically 6–12 patients per supervised session
Referral Criteria
- MRC dyspnoea grade ≥3 (or ≥2 with significant functional limitation)
- Stable COPD (or 4+ weeks post-exacerbation)
- FEV1 any level — benefit seen across all GOLD grades
- Motivated and able to participate in exercise
- Other: IPF, bronchiectasis, pulmonary hypertension (adapted programme)
Programme Components
Aerobic Training
- Walking (treadmill or ground-based)
- Stationary cycling
- Target: 60–80% peak work rate (Borg 4–6)
- Interval training option for severe dyspnoea
- Duration: 20–60 min per session
Resistance Training
- Upper limb: Shoulder press, arm curls, rowing
- Lower limb: Leg press, squats, step-ups
- 8–12 repetitions, 2–3 sets
- 60–70% 1-rep maximum
- Improves peripheral muscle function
Education Modules
- Disease self-management & action plans
- Inhaler technique optimisation
- Energy conservation techniques
- Smoking cessation support
- Breathlessness management strategies
- Nutrition and weight management
Psychological & Nutritional Support
- Anxiety and depression screening (HADS)
- Cognitive behavioural therapy referral if indicated
- Nutritional assessment: BMI, MUST score
- Supplementation for underweight patients (BMI <21)
- Dyspnoea coping strategies
Assessment Tools
| Tool | Measures | MCID (Minimal Clinically Important Difference) |
|---|---|---|
| 6-Minute Walk Test (6MWT) | Functional exercise capacity (metres) | ≥30m (some cite ≥54m for COPD) |
| Incremental Shuttle Walk Test (ISWT) | Maximal exercise capacity | ≥47.5m |
| CAT Score | COPD impact on daily life (0–40) | ≥2 points |
| mMRC Scale | Dyspnoea grade (0–4) | 1 grade |
| HADS | Anxiety (0–21) & Depression (0–21) | ≥1.5 points; ≥8 = borderline case |
| SGRQ | Health-related quality of life (0–100, lower=better) | ≥4 points |
Contraindications to Pulmonary Rehabilitation
Absolute Contraindications
- Unstable angina or NSTEMI within 4 weeks
- Uncontrolled hypertension (SBP >180 / DBP >110 mmHg)
- Severe pulmonary hypertension (mPAP >55 mmHg)
- Acute exacerbation (start PR after stabilisation)
Relative Contraindications
- Locomotor disability preventing exercise
- Cognitive impairment preventing active participation
- Active psychiatric illness
- Severe comorbidity limiting exercise (e.g., severe cardiac failure)
- Social/logistic barriers (consider home-based PR)
Breathing Techniques
Pursed Lip Breathing (PLB) — Teaching Steps
PLB reduces respiratory rate, decreases air trapping, improves alveolar ventilation and reduces dyspnoea. Particularly useful in emphysema where dynamic airway collapse occurs on expiration.
- Position the patient comfortably — sitting upright or forward-lean position
- Instruct patient to relax shoulders and neck muscles
- Inhale through the nose — gently, for 2 seconds (mouth closed)
- Purse lips as if about to whistle or blow out a candle
- Exhale slowly through pursed lips — for 4 seconds (2:4 ratio minimum)
- Do NOT force or push air out — passive, relaxed exhalation
- Repeat for 5–10 breath cycles; use during activity or dyspnoea episodes
- Teach patient to use during exertion (stairs, walking, dressing)
Physiological Effects
- Creates back-pressure preventing early airway collapse (splints airways)
- Prolongs expiratory time → reduces dynamic hyperinflation (air trapping)
- Decreases respiratory rate and work of breathing
- Reduces sensation of dyspnoea
- Improves SpO2 and gas exchange in some patients
Diaphragmatic (Abdominal) Breathing
- Patient places one hand on chest, one on abdomen
- Inhale: abdomen rises, chest remains relatively still
- Exhale: abdomen falls; can assist with gentle hand pressure
- Improves diaphragm recruitment and efficiency
- Reduces accessory muscle use
- Can be combined with pursed lip breathing
Diaphragmatic breathing may increase work of breathing in some COPD patients with hyperinflation — individualise based on patient response.
Active Cycle of Breathing Technique (ACBT)
A structured sequence used for airway clearance — particularly useful in bronchiectasis and COPD with excess secretions.
| Phase | Description | Purpose |
|---|---|---|
| 1. Breathing Control (BC) | Gentle, relaxed, diaphragmatic breathing at tidal volume — 3–5 breaths | Rest between active phases; reduces bronchospasm |
| 2. Thoracic Expansion Exercises (TEE) | 3–5 deep breaths with 3-second inspiratory hold; can add chest clapping/vibration | Loosens and mobilises secretions peripherally |
| 3. Forced Expiration Technique (FET) — Huff | 1–2 forced expirations (huffing) from mid-to-low lung volume, then breathing control | Moves secretions centrally for expectoration |
Cycle: BC → TEE → BC → FET → BC. Repeat 3–4 cycles until airway clearance achieved. Huff = open glottis forced expiration (not cough).
Positive Expiratory Pressure (PEP) Devices
- Creates 10–20 cmH2O back-pressure during expiration
- Splints airways open, moves air behind secretions
- Types: fixed orifice PEP mask, oscillating PEP (Flutter, Acapella)
- Oscillating PEP adds airway vibration to loosen secretions
- Used 2–4 times daily during exacerbations
- Particularly useful in COPD with bronchiectatic changes
Incentive Spirometry
- Volume-oriented (e.g., Voldyne) or flow-oriented (e.g., Triflo) devices
- Visual feedback encourages sustained maximal inspiration
- Primary use: post-operative atelectasis prevention
- Limited evidence in COPD specifically; more useful in restrictive conditions
- Technique: slow, deep inhalation to raise float/ball, hold 3–5 seconds
NIV (CPAP/BiPAP) for Acute Exacerbations — Evidence & Protocol
GOLD Evidence: Non-Invasive Ventilation (NIV/BiPAP) reduces intubation rate by 46%, reduces mortality, and decreases length of ICU stay in AECOPD with respiratory acidosis.
BiPAP Indications in AECOPD
- Respiratory acidosis: pH 7.25–7.35 + PaCO2 >6 kPa
- Severe dyspnoea with signs of respiratory muscle fatigue
- Respiratory rate >25 breaths/min despite controlled O2
- Failure to improve on medical therapy
Initial Settings (BiPAP)
- IPAP: 10–15 cmH2O (titrate to comfort and tidal volume)
- EPAP: 4–5 cmH2O (PEEP to oppose intrinsic PEEP)
- Backup rate: 12–16 breaths/min
- FiO2: titrate to SpO2 88–92%
Escalation threshold: pH <7.25 or rising PaCO2 on NIV after 1–2 hours = escalate to ITU / intubation discussion
Positioning for Dyspnoea Relief
| Position | Technique | Benefit |
|---|---|---|
| High sitting (90°) | Upright in chair or bed backrest at 90° | Reduces abdominal pressure on diaphragm; improves FRC and diaphragm descent |
| Forward lean (tripod) | Lean forward 30–45° elbows on knees or table | Fixes shoulder girdle; allows scalene and sternocleidomastoid to assist breathing; improves diaphragm mechanics |
| Side-lying | Lie on unaffected side | Improves V/Q matching in unilateral lung pathology |
| Orthopnoea position | Sleeping with extra pillows/head elevated | Reduces dyspnoea at night; common patient adaptation |
Inhaler Technique & Adherence
Inhaler Device Selection Algorithm
| Factor | Favours MDI ± Spacer | Favours DPI | Favours Nebuliser |
|---|---|---|---|
| Inspiratory flow | Any flow rate acceptable | Requires peak flow >30–60 L/min | No inspiratory effort needed |
| Co-ordination | Poor co-ordination → use spacer | No co-ordination needed (breath-actuated) | No co-ordination needed |
| Cognitive ability | Spacer simplifies technique | Simple to use once taught | Minimal patient skill required |
| Setting | Community/hospital | Community preferred | Hospital/acute setting; home for severe COPD |
| Dose | Lower doses | Lower-to-medium doses | Higher doses; acute exacerbation |
Always ask patient to demonstrate inhaler technique at every consultation. Up to 90% of patients make at least one critical error in technique.
MDI (Pressurised Metered-Dose Inhaler) Technique
- Prime new inhaler (4 test sprays) or after >14 days non-use
- Shake vigorously 5 times
- Exhale fully away from mouthpiece (do not exhale into device)
- Place mouthpiece in mouth, seal lips tightly around it
- Actuate at start of a slow, deep inhalation (3–5 seconds to full lung capacity)
- Hold breath for 10 seconds (or as long as comfortable)
- Wait 30–60 seconds between puffs
- Rinse mouth after ICS (prevents oral candidiasis)
Spacer use: Recommended for poor coordination, children, elderly, high-dose ICS. Reduces oropharyngeal deposition and candidiasis risk.
DPI (Dry Powder Inhaler) Technique
- Load the dose as per device instructions (twist, click, or pierce)
- Hold device level (most DPIs) or as directed
- Exhale fully — away from device (moisture from breath deactivates powder)
- Seal lips tightly around mouthpiece
- Inhale forcefully and deeply as fast as possible (turbulent flow disperses powder)
- Hold breath for 10 seconds
- Exhale away from device; do not exhale back into DPI
- Rinse mouth after ICS
No spacer with DPI — spacer is contraindicated with dry powder inhalers. Peak inspiratory flow must be sufficient (>30–60 L/min depending on device).
Common Critical Inhaler Errors
| Error | Device | Consequence |
|---|---|---|
| Not exhaling before inhalation | MDI & DPI | Reduced lung volume available; reduced drug deposition |
| Inhaling too fast (high flow) | MDI | Drug impacts oropharynx; central deposition; local side effects |
| Inhaling too slowly (low flow) | DPI | Insufficient turbulence to de-aggregate powder; dose not delivered |
| Exhaling into DPI | DPI | Moisture clumps powder; device blocked; dose lost |
| Not shaking MDI | MDI | Inconsistent propellant:drug ratio; dose error |
| Actuating before or after inhalation | MDI | Drug deposited in mouth/air, not lungs |
| Not rinsing mouth after ICS | MDI & DPI | Oropharyngeal candidiasis, dysphonia |
Nebuliser Use — COPD Safety Considerations
CRITICAL: In COPD patients, nebulisers should be oxygen-driven at 6–8 L/min but must NOT use high-flow O2 (100% non-rebreather mask) as the driving gas continuously — use a Venturi 28% controlled mask for oxygen simultaneously if needed.
- Driving gas risk: COPD patients may rely on hypoxic respiratory drive — high-flow 100% O2 can cause CO2 retention and respiratory acidosis (Haldane effect + hypoxic drive suppression)
- Target SpO2: 88–92% in COPD during nebulisation
- Driving gas: Air + supplemental Venturi O2 is safer than 100% O2 driving
- Bronchodilators via nebuliser: Salbutamol 2.5–5mg + Ipratropium 500mcg in acute exacerbation
- Face mask vs mouthpiece: Mouthpiece preferred (less nasal deposition); mask if patient cannot hold mouthpiece
Inhaler Adherence Assessment
- MARS (Medication Adherence Report Scale): 5-item self-report questionnaire; score 5–25; <22 = non-adherence
- Check prescription refill frequency (dose counter or pharmacy records)
- Non-adherence reasons: forgetfulness, side effects, embarrassment, cost, belief system
- Intentional vs non-intentional non-adherence — address differently
Spacer Cleaning Protocol
- Clean spacer monthly (or per manufacturer guidance)
- Dismantle; soak in warm soapy water 15–30 minutes
- Air-dry only — do NOT towel or cloth dry (creates static charge that reduces drug delivery)
- Replace spacer every 6–12 months or if cracked/discoloured
COPD Exacerbations
Definition & Triggers
Definition: An acute worsening of respiratory symptoms that is beyond normal day-to-day variation and leads to a change in medication.
Common Triggers
- Respiratory infection (70–80%): viral > bacterial
- Viral: Rhinovirus most common (30%), then Influenza, RSV
- Bacterial: H. influenzae, S. pneumoniae, M. catarrhalis, P. aeruginosa (severe COPD)
- Air pollution, dust storms, cold air, allergens
- Poor adherence to maintenance therapy
- Cardiac arrhythmia or heart failure
Anthonisen Criteria (1987)
- Type I: All 3 cardinal symptoms present
- Type II: Any 2 of 3 cardinal symptoms
- Type III: 1 cardinal symptom + ≥1 of: URTI <5 days, fever, increased wheeze, ↑HR or RR >20%
Cardinal symptoms:
- Increased dyspnoea
- Increased sputum volume
- Increased sputum purulence
Controlled Oxygen Delivery Guide — AECOPD
DO NOT use non-rebreather mask (100% O2) in COPD. Target SpO2 88–92% in ALL COPD patients — verified or suspected. High-flow O2 causes CO2 retention and hypercapnic respiratory failure.
| Device | FiO2 | Flow Rate | Use in COPD |
|---|---|---|---|
| Venturi mask 24% | 0.24 | 2–3 L/min | First-line in COPD exacerbation (SpO2 <88%) |
| Venturi mask 28% | 0.28 | 4 L/min | If SpO2 remains <88% on 24% Venturi |
| Nasal cannula | 0.24–0.40 | 1–4 L/min | Acceptable; less precise — use cautiously |
| Simple face mask | 0.35–0.50 | 5–10 L/min | Avoid in COPD — FiO2 too variable |
| Non-rebreather mask | 0.60–1.0 | 10–15 L/min | CONTRAINDICATED in COPD |
Check ABG after 30–60 min on O2 therapy. Titrate to maintain SpO2 88–92%. Document O2 as a drug (prescription required).
AECOPD Management Algorithm
| Intervention | Details | Evidence Level |
|---|---|---|
| Controlled O2 | Target SpO2 88–92%; Venturi 24–28% | GOLD A |
| SABA nebuliser | Salbutamol 2.5–5mg q20min × 3, then 4-hourly | GOLD A |
| SAMA nebuliser | Ipratropium 500mcg q6h (add to SABA) | GOLD A |
| Systemic steroids | Prednisolone 30–40mg oral × 5 days (non-inferior to longer course) | GOLD A |
| Antibiotics | If purulent sputum (Type I/II Anthonisen) — Amoxicillin 500mg TDS or Doxycycline 200mg OD × 5 days; use Augmentin or Clarithromycin if resistant | GOLD B |
| NIV (BiPAP) | pH 7.25–7.35 + hypercapnia — reduces intubation by 46%, reduces mortality | GOLD A |
| DVT prophylaxis | LMWH + TED stockings (immobile patients) | GOLD B |
| Nutritional support | Ensure adequate caloric intake; NG if unable to eat | GOLD C |
DECAF Score — Mortality Prediction in AECOPD
DECAF predicts in-hospital mortality in acute COPD exacerbation. Validated in UK hospitals.
| Variable | Score |
|---|---|
| Extended MRC dyspnoea scale eMRCD 5a (too breathless to undress but washes independently) | 1 |
| Extended MRC dyspnoea scale eMRCD 5b (too breathless to wash/dress independently) | 2 |
| Eosinopenia (eosinophils <0.05 × 10⁹/L) | 1 |
| Consolidation on CXR | 1 |
| Acidaemia (pH <7.30) | 1 |
| Atrial Fibrillation (on ECG or history) | 1 |
Total 0–6. Score 0–1: low mortality (<2%), Score 3–6: high mortality (>25%). Guide HDU/ICU triage decisions.
COPD Exacerbation Severity & Management Guide
O2 Target
NIV Indication
Escalation Threshold
Immediate Actions
GCC Context — COPD & Pulmonary Rehabilitation
COPD Epidemiology in GCC
- Tobacco smoking remains the primary risk factor
- Shisha/Waterpipe smoking: One hour of shisha = 100–200× the smoke volume of a single cigarette; significant COPD risk; culturally normalised in GCC
- Indoor air quality: sand and dust storms are major exacerbation triggers (PM2.5/PM10 spikes)
- Biomass fuel burning in rural areas (Oman, Yemen border regions)
- COPD prevalence underdiagnosed due to limited spirometry access
- GCC countries show rising COPD burden with urbanisation
Dust Storm COPD Exacerbation Surge
- Haboob (dust storm) events: sharp rise in hospital COPD admissions within 24–48h
- PM10 levels can exceed 1,000 µg/m³ during major storms
- Nursing actions during dust storm warnings:
- Advise COPD patients to stay indoors; close windows; use air purifiers
- Pre-emptive dose of SABA (salbutamol 2 puffs PRN)
- Activate exacerbation action plan if symptoms worsen
- Hospital surge preparation: stock nebulisers, Venturi masks, BiPAP
- GCC Health Ministries issue seasonal air quality alerts — integrate with discharge planning
Pulmonary Rehabilitation in GCC
- Formal PR programmes are developing — limited dedicated centres vs UK/Europe
- Available at tertiary hospitals: King Faisal Specialist Hospital (SA), Cleveland Clinic Abu Dhabi, Hamad Medical (Qatar)
- Telemedicine PR programmes gaining traction post-COVID-19 pandemic
- Cultural considerations: gender-segregated exercise facilities; family involvement in education
- Ramadan adaptations: shift programme timing; hydration strategies post-Iftar
- Heat and humidity: outdoor exercise contraindicated in summer — indoor facilities essential
Regulatory & Licensing Frameworks
- DHA (Dubai Health Authority): Respiratory nursing scope includes inhaler technique education, PR referral, LTOT monitoring
- DOH (Dept. of Health Abu Dhabi): Respiratory competencies aligned with GOLD guidelines; structured clinical education requirements
- SCFHS (Saudi Commission for Health Specialties): Pulmonary nursing content in specialty examinations — COPD management, NIV nursing, PR referral pathways
- HAAD/MOH Qatar/Bahrain: Continuing Professional Development (CPD) requirements for respiratory nursing practice
Ramadan and COPD — Inhaler Use Guidance
Key Islamic ruling (Fatwa): Inhaled medications (MDI, DPI, nebuliser) do NOT break the fast — they do not reach the stomach and have no nutritional value. Patients must NOT stop their inhalers during Ramadan.
- Source: Islamic Fiqh Academy (OIC) — majority ruling confirms inhalers permissible during fasting
- Nursing role: reassure and educate patients that stopping inhalers is medically dangerous and not required
- Adjust timing: Long-acting inhalers (once-daily LAMA/LABA) can be taken at Suhoor or Iftar
- Twice-daily inhalers: adjust to Suhoor + Iftar to avoid the fasting hours
- Monitor closely for exacerbations during Ramadan — dehydration, altered sleep patterns, temperature changes all increase risk
- Systemic steroids and oral antibiotics: do break the fast — discuss with religious scholar if needed; medical necessity takes precedence (Islamic principle of necessity — Dharura)
GCC Exam Preparation — 5 MCQs
Click on an answer to reveal explanation.
1. A patient with COPD is admitted with an exacerbation. SpO2 is 84% on room air. Which oxygen delivery device is MOST appropriate?
Correct: B — Venturi mask 24%. In COPD, the target SpO2 is 88–92%. Venturi masks deliver precise, controlled FiO2. A non-rebreather mask delivers near 100% O2 and risks CO2 retention and hypercapnic respiratory failure in COPD patients who may rely on hypoxic drive. A simple face mask provides imprecise FiO2 (35–50%) — too high and uncontrolled.
2. According to GOLD guidelines, which combination of blood eosinophil count and clinical feature is the STRONGEST indication to add Inhaled Corticosteroid (ICS) to a COPD patient's regimen?
Correct: C — Eosinophils ≥300 cells/µL is the threshold that most strongly predicts ICS response. Combined with frequent exacerbations (≥2 moderate/year or ≥1 hospitalisation), this is the clearest indication. Option A: eosinophils <100 cells/µL is associated with ICS resistance and increased pneumonia risk. Option D: eosinophils <100 — ICS should be avoided.
3. A nurse is teaching a COPD patient the active cycle of breathing technique (ACBT) for airway clearance. What is the correct sequence of phases?
Correct: C. The ACBT cycle always begins and ends with breathing control (BC) to prevent bronchospasm. TEE loosens peripheral secretions; BC provides recovery; FET (huff) moves secretions centrally. Coughing is not part of ACBT — the FET/huff replaces uncontrolled coughing, which can cause airway collapse in COPD.
4. A patient with COPD is admitted with exacerbation. ABG shows pH 7.29, PaCO2 9.2 kPa, PaO2 7.8 kPa on controlled O2. What is the PRIORITY nursing intervention?
Correct: B — Prepare for NIV (BiPAP). pH 7.29 + hypercapnia (PaCO2 9.2 kPa) = respiratory acidosis. GOLD guidelines strongly recommend NIV for pH 7.25–7.35. pH <7.25 requires immediate HDU/ITU escalation and intubation discussion. Increasing to non-rebreather O2 (A) would worsen CO2 retention. IV aminophylline (C) has limited role and significant side effects. NIV reduces intubation by 46% and mortality.
5. During Ramadan, a Muslim patient with severe COPD asks whether he must stop his tiotropium (Spiriva) inhaler while fasting. What is the CORRECT nursing response?
Correct: C. The Islamic Fiqh Academy ruling confirms inhaled medications do NOT break the Ramadan fast — they do not reach the stomach and have no nutritional value. Nurses must reassure patients and ensure adherence. Tiotropium is once-daily — can be taken at Suhoor or Iftar. Stopping inhalers during Ramadan risks severe exacerbation and hospitalisation. Oral bronchodilators (D) would break the fast and are generally inferior to inhaled therapy for COPD.